Table 1.
Cell line models and the in vitro assay end points used to determine drug potency
| Target | Drug | Cell line | End point |
|---|---|---|---|
| ABL | Bosutinib | K562 | Proliferation |
| Dasatinib | K562 | Apoptosis | |
| Imatinib | K562 | Proliferation | |
| Nilotinib | K562 | Apoptosis | |
| Ponatinib | Ba/F3 | Apoptosis | |
| ALK | Alectinib | KARPAS‐299 | Proliferation |
| Ceritinib | KARPAS‐299 | Proliferation | |
| Crizotinib | KARPAS‐299 | Proliferation | |
| BRAF | Dabrafenib | COLO205 | Proliferation |
| Encorafenib | A375 | Proliferation | |
| Vemurafenib | COLO205 | Proliferation | |
| CDK4/6 | Abemaciclib | EFM‐19 | Proliferation |
| Palbociclib | EFM‐19 | Proliferation | |
| Ribociclib | Not applicable | Not applicable | |
| EGFR | Afatinib | HCC827 | Proliferation |
| Erlotinib | H3255 | Proliferation | |
| Gefitinib | HCC827 | Proliferation | |
| Osimertinib | H1975 | Proliferation | |
| MEK1/2 | Binimetinib | COLO205 | Proliferation |
| Cobimetinib | COLO205 | Proliferation | |
| Trametinib | COLO205 | Proliferation | |
| PARP | Niraparib | CAPAN‐1 | Proliferation |
| Olaparib | ES7 | Viability | |
| Rucaparib | ES7 | Viability | |
| Talazoparib | ES7 | Viability |